Trial · NCT02646540
AiDing Diuresis wIth Tolvaptan (ADD-IT)
NCT02646540, Phase 1, Completed, Emory University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. AiDing Diuresis wIth Tolvaptan (ADD-IT). Trials, record NCT02646540. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02646540
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- AiDing Diuresis wIth Tolvaptan (ADD-IT)
- NCT number
- NCT02646540
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 14 participants, actual
- Lead sponsor
- Emory University
- Conditions
- Cardiomyopathy, Congestive Heart Failure
- Interventions
- Tolvaptan 30 mg + IV Diuretics, Metolazone 5 mg + IV Diuretics, 2.5 times the Diuretics Dose
- First posted
- 2016-01-05
- Last updated
- 2019-03-27
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Length of Hospitalization Measured in Days | Duration of Hospitalization (Average of Five Days) | The number of days hospitalized until discharge. |
| Secondary | Change in Body Weight | Baseline (hospital admission), Discharge (Average of 5 Days) | The difference in body weight from hospital admission to discharge measured in kilograms. |
| Secondary | Total Diuretic Dose | Up to Five Days | The total dose of diuretics given throughout the duration of hospitalization measured in milligrams (mg). |
| Secondary | Change in estimated glomerular filtration rate (eGFR) | Baseline (hospital admission), Discharge (Average of 5 days) | The difference in eGFR from baseline (hospital admission) to discharge. |
| Secondary | Number of Days Alive | Post Hospital Discharge (30 days) | The number of days participants remain alive over thirty days after hospital discharge. |
| Secondary | Rate of Re-Hospitalization | 30 Days Post Hospitalization | The number of participants re-hospitalized for worsening heart failure or death at 30 days. |
| Secondary | Number of Electrolyte Imbalance Related Adverse Events | Duration of Hospitalization (Average of Five Days) | The number of adverse events due to electrolyte imbalance throughout the duration of hospitalization. |
| Secondary | Number of Participants Requiring Electrolyte Repletion | Duration of Hospitalization (Average of Five Days) | The number of participants that require electrolyte repletion throughout the duration of hospitalization. |
| Secondary | Change in Sodium Level | Baseline (hospital admission), Discharge (Average of 5 days) | The difference in sodium levels from baseline to hospital discharge measured in milliequivalents per liter (mEqL). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02646540
GET https://conductscience.org/api/trials/v1/NCT02646540/registered